Literature DB >> 11021765

Epidermal growth factor influenced by opioid peptides in immature rat uterus.

Z Vértes1, A Sándor, K A Kovács, A Oszter, J L Környei, S Kovács, M Vértes.   

Abstract

The aim of the present experiment was to investigate the effect of [D-Met2,Pro5] enkephalinamide (ENK) implantation on the development of the uterus during 8-33 days of age and the involvement of epidermal growth factor (EGF) in the effect. Administration of ENK was attained by osmotic minipumps (5 microg/h) implanted intraperitoneally. ENK resulted in a decrease in the EGF content of the uterus, which was already significant after 48 h of the implantation. The DNA content 24 and 48 h after the treatment decreased, no change at 72 h was found, however the protein/DNA ratio on the effect of ENK treatment was significantly decreased at this time in all examined age groups. High affinity and lower capacity competitive naloxone binding sites were demonstrated in the membrane fraction of the uteri. Seventy-two h after ENK treatment the binding capacity of these sites significantly dropped. The present results suggest a novel multiple interaction between estrogen and two probably paracrine hormones, EGF and opioid peptide, in the regulation of growth and development of the uterus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021765     DOI: 10.1007/BF03343765

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

2.  Modulation of thymidine incorporation by kappa-opioid ligands in rat spinal cord-dorsal root ganglion co-cultures.

Authors:  J Barg; S Y Nah; R Levy; D Saya; Z Vogel
Journal:  Brain Res       Date:  1993-11-26       Impact factor: 3.252

3.  A superactive antinociceptive pentapeptide, (D-Met2, Pro5)-enkephalinamide.

Authors:  S Bajusz; A Z Rónai; J I Székely; L Gráf; Z Dunai-Kovács; I Berzétei
Journal:  FEBS Lett       Date:  1977-04-01       Impact factor: 4.124

4.  On the mechanism of opioid-oestradiol interactions.

Authors:  M Vértes; Z Pámer; J Garai
Journal:  J Steroid Biochem       Date:  1986-01       Impact factor: 4.292

5.  Opioid peptides inhibit the estradiol-induced proliferation of cultured rat uterine cells.

Authors:  J L Környei; Z Vértes; A Oszter; S Kovács; M Vértes
Journal:  Eur J Pharmacol       Date:  1997-10-01       Impact factor: 4.432

6.  In vitro effects of cytosolic inhibitor and opiates on the binding of [3H]oestradiol to nuclear type II binding sites of rat uterus and hypothalamus.

Authors:  J Garai; M Vértes; S Kovács
Journal:  J Steroid Biochem       Date:  1989-03       Impact factor: 4.292

7.  Changes of [3H]naloxone binding in oestrogen stimulated rat uterus.

Authors:  Z Vértes; T Ordög; M Vértes; S Kovács
Journal:  J Steroid Biochem Mol Biol       Date:  1993-12       Impact factor: 4.292

8.  Ovarian and adrenal contributions to postnatal growth and differentiation of the rat uterus.

Authors:  W S Branham; D M Sheehan
Journal:  Biol Reprod       Date:  1995-10       Impact factor: 4.285

9.  Steroids and opioid receptors.

Authors:  S Schwarz; P Pohl
Journal:  J Steroid Biochem Mol Biol       Date:  1994-03       Impact factor: 4.292

10.  Effect of naloxone and D-met2-pro5-enkephalinamide treatment on the DNA synthesis in the developing rat brain.

Authors:  Z Vértes; G Melegh; M Vértes; S Kovács
Journal:  Life Sci       Date:  1982-07-12       Impact factor: 5.037

View more
  1 in total

1.  Developmental changes in the inhibition of cultured rat uterine cell proliferation by opioid peptides.

Authors:  J L Környei; Z Vértes; K A Kovács; P M Göcze; M Vértes
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.